$REPL

$13.05 +$0.58 (4.65%) Close

$REPL Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$REPL Management Team

Mr. Philip Astley-Sparke

Executive Chairman of the Board

Age 54

Compensation $6.018M USD

Sex Male

Dr. Sushil Patel

Chief Executive Officer

Director

Age 54

Compensation $3.698M USD

Sex Male

Ms. Emily Hill

Chief Financial Officer

Age 45

Compensation $1.595M USD

Sex Female

Mr. Christopher Sarchi

Chief Commercial Officer

Age 55

Compensation -

Sex Male

Dr. Konstantinos Xynos

Chief Medical Officer

Age 59

Compensation $1.625M USD

Sex Male

Mr. Christopher Brinzey

Investor Relations

Age -

Compensation -

Sex Male

Name / Title	Age	Compensation	Sex
Mr. Philip Astley-Sparke Executive Chairman of the Board	54	$6.018M USD	Male
Dr. Sushil Patel Chief Executive Officer Director	54	$3.698M USD	Male
Ms. Emily Hill Chief Financial Officer	45	$1.595M USD	Female
Mr. Christopher Sarchi Chief Commercial Officer	55	-	Male
Dr. Konstantinos Xynos Chief Medical Officer	59	$1.625M USD	Male
Mr. Christopher Brinzey Investor Relations	-	-	Male

Board of Directors

From the proxy statement filed Jul 29, 2026

Directors

serving now

Independent

8 of 10

stated in the proxy

Average tenure

5.6 years

from year joined

CEO also chairs the board

Philip Astley-Sparke

Director	Age	On board	Independent	Committees	Other public boards	2026 pay
Philip Astley-Sparke Board chair	Not stated	2015 11 years	Not independent	None stated	enGene Therapeutics Inc.	Not stated
Sushil Patel CEO	Not stated	2024 2 years	Not independent	None stated	Revolution Medicines, Inc.	Paid as CEO
Madhavan Balachandran	Not stated	2024 2 years	Independent	None stated	uniQure, N.V., Stevanato Group S.p.A	$231,108
Kapil Dhingra	Not stated	2017 9 years	Independent	Compensation Committee Research & Development Committee · Chair	Black Diamond Therapeutics, Inc.	$246,108
Michael Goller	Not stated	2025 1 year	Independent	Nominating and Corporate Governance Committee	DBV Technologies S.A.	$50,000
Christy Oliger	Not stated	2021 5 years	Independent	Compensation Committee · Chair Research & Development Committee	Karyopharm Therapeutics Inc., Vera Therapeutics, Inc.	$246,108
Veleka R. Peeples-Dyer Leaving at the meeting	Not stated	2023 3 years	Independent	Nominating and Corporate Governance Committee Audit Committee	None stated	$238,608
Paolo Pucci Leaving at the meeting	Not stated	2020 6 years	Independent	Nominating and Corporate Governance Committee Research & Development Committee	West Pharmaceuticals Services, Inc.	$236,108
Joseph Slattery	Not stated	2017 9 years	Independent	Compensation Committee Audit Committee · Chair	None stated	$251,108
Dieter Weinand Lead independent director	Not stated	2018 8 years	Independent	Nominating and Corporate Governance Committee · Chair Audit Committee	Coya Therapeutics, Evotec SE	$278,608

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Jul 29, 2026 states there were none.

Read it in the proxy

Comments

Company Executives

$REPL Management Team

Mr. Philip Astley-Sparke

Dr. Sushil Patel

Ms. Emily Hill

Mr. Christopher Sarchi

Dr. Konstantinos Xynos

Mr. Christopher Brinzey

Board of Directors

Related-party transactions

No related-party transactions disclosed